Business
Jul 2, 2026
Seoul, South Korea, and Shanghai, China, 2 July 2026 — Alvogen Korea Co., Ltd., ("Alvogen Korea") a wholly owned subsidiary of Lotus Pharmaceutical Co., Ltd. (Taiwan Stock Exchange: 1795), and Shanghai Henlius Biotech (“Henlius”, Ho...
Business
Jun 29, 2026
Taipei, Taiwan, and Morristown, N.J., June 29, 2026 - Lotus Pharmaceutical Co., Ltd. (TWSE: 1795, “Lotus” or the “Company”) today announced that Norwich Pharmaceuticals, Inc. (“Norwich”), a wholly owned subsidiary ...
Investors
Jun 10, 2026
Taipei, Taiwan, 10 June 2026 — Lotus Pharmaceutical Co., Ltd. (Taiwan Stock Exchange: 1795), a global pharmaceutical leader based in Taiwan, today announced its unaudited consolidated revenue for May 2026 of NT$2,324 million, representing an in...
Business
May 21, 2026
Taipei, Taiwan, 21 May 2026 — Lotus Pharmaceutical Co., Ltd. (Taiwan Stock Exchange: 1795), a global pharmaceutical company headquartered in Taiwan, today announced that it has entered into an agreement with OM Pharma, a global biopharmaceutica...
Investors
May 11, 2026
Taipei, Taiwan, 11 May 2026 — Lotus Pharmaceutical (1795:TT; “Lotus” or “the Company”), a multinational pharmaceutical company, announced its audited financial results for the first quarter ended March 31 2026, deliverin...
Investors
May 11, 2026
Taipei, Taiwan, 11 May 2026 — Lotus Pharmaceutical Co., Ltd. (Taiwan Stock Exchange: 1795), a global pharmaceutical leader based in Taiwan, today announced its unaudited consolidated revenue for April 2026 of NT$3,086 million, representing...
Business
May 4, 2026
Taipei, Taiwan, 4 May 2026 — Lotus Pharmaceutical Co., Ltd. (Taiwan Stock Exchange: 1795), a global pharmaceutical company headquartered in Taiwan, today announced the successful global launch of its Nintedanib soft gel capsules (100mg and 150m...
Investors
Apr 10, 2026
Taipei, Taiwan, 10 April 2026 — Lotus Pharmaceutical Co., Ltd. (Taiwan Stock Exchange: 1795), a global pharmaceutical leader based in Taiwan, today announced its unaudited consolidated revenues for March 2026 of NT$4,354 million, represent...
Business
Apr 8, 2026
Taipei, Taiwan, 08 April 2026 — Lotus Pharmaceutical Co., Ltd. (Taiwan Stock Exchange: 1795), a global pharmaceutical company headquartered in Taiwan, today announced that Zepzelca® (lurbinectedin), its licensed oncology product, has receiv...
